These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 18958845)

  • 1. PERISCOPE and the effect of pioglitazone on the progression of coronary artery disease in patients with diabetes.
    Marx N
    Diab Vasc Dis Res; 2008 Nov; 5(4):345-6. PubMed ID: 18958845
    [No Abstract]   [Full Text] [Related]  

  • 2. PERISCOPE: pioglitazone offers the right cluster of effects to confer benefit in type 2 diabetes.
    Cardiovasc J Afr; 2008; 19(3):159-62. PubMed ID: 18568180
    [No Abstract]   [Full Text] [Related]  

  • 3. Lowering the triglyceride/high-density lipoprotein cholesterol ratio is associated with the beneficial impact of pioglitazone on progression of coronary atherosclerosis in diabetic patients: insights from the PERISCOPE (Pioglitazone Effect on Regression of Intravascular Sonographic Coronary Obstruction Prospective Evaluation) study.
    Nicholls SJ; Tuzcu EM; Wolski K; Bayturan O; Lavoie A; Uno K; Kupfer S; Perez A; Nesto R; Nissen SE
    J Am Coll Cardiol; 2011 Jan; 57(2):153-9. PubMed ID: 21211686
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Seeking alternatives to Hard End Points: is imaging the best APPROACH?
    Finn AV; Chandrashekhar Y; Narula J
    Circulation; 2010 Mar; 121(10):1165-8. PubMed ID: 20194886
    [No Abstract]   [Full Text] [Related]  

  • 5. Pioglitazone vs glimepiride in the PERISCOPE trial.
    Shah R
    JAMA; 2008 Aug; 300(7):787-8; author reply 788. PubMed ID: 18714054
    [No Abstract]   [Full Text] [Related]  

  • 6. Pioglitazone vs glimepiride in the PERISCOPE trial.
    Fresco C
    JAMA; 2008 Aug; 300(7):787; author reply 788. PubMed ID: 18714055
    [No Abstract]   [Full Text] [Related]  

  • 7. CHICAGO, PERISCOPE and PROactive: CV risk modification in diabetes with pioglitazone.
    Betteridge DJ
    Fundam Clin Pharmacol; 2009 Dec; 23(6):675-9. PubMed ID: 19744248
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Different effects of thiazolidinediones on target vessel revascularization with bare metal stents: a meta-analysis.
    Nishio K; Kobayashi Y
    Cardiovasc Revasc Med; 2010; 11(4):227-31. PubMed ID: 20934654
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Response to letter regarding article, "rosiglitazone and outcomes for patients with diabetes mellitus and coronary artery disease in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Trial".
    Bach RG; Brooks MM; Lombardero M; Genuth S; Donner TW; Garber A; Kennedy L; Monrad ES; Pop-Busui R; Kelsey SF; Frye RL;
    Circulation; 2014 Apr; 129(16):e460-1. PubMed ID: 24753557
    [No Abstract]   [Full Text] [Related]  

  • 10. Pioglitazone versus glimepiride on coronary artery calcium progression in patients with type 2 diabetes mellitus: a secondary end point of the CHICAGO study.
    Davidson MH; Beam CA; Haffner S; Perez A; D'Agostino R; Mazzone T
    Arterioscler Thromb Vasc Biol; 2010 Sep; 30(9):1873-6. PubMed ID: 20576945
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Evidences demonstrating the effects of anti-atherosclerotic actions of pioglitazone--special emphasis on PROactive Study and PERISCOPE Study].
    Kawamori R
    Nihon Rinsho; 2010 Feb; 68(2):235-41. PubMed ID: 20158090
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial.
    Mazzone T; Meyer PM; Feinstein SB; Davidson MH; Kondos GT; D'Agostino RB; Perez A; Provost JC; Haffner SM
    JAMA; 2006 Dec; 296(21):2572-81. PubMed ID: 17101640
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The effect of glitazones on the progression of type 2 diabetes and on cardiovascular endpoints].
    Schatz H
    Dtsch Med Wochenschr; 2005 Aug; 130(31-32):1825-30. PubMed ID: 16052448
    [No Abstract]   [Full Text] [Related]  

  • 14. [Prospective pioglitazone clinical trial in macrovascular events].
    Asanuma H; Kitakaze M
    Nihon Rinsho; 2012 May; 70 Suppl 3():301-8. PubMed ID: 22768537
    [No Abstract]   [Full Text] [Related]  

  • 15. How well does the evidence on pioglitazone back up researchers' claims for a reduction in macrovascular events?
    Freemantle N
    BMJ; 2005 Oct; 331(7520):836-8. PubMed ID: 16210286
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of pioglitazone on nitric oxide synthase in patients with type 2 diabetes mellitus.
    Nishio K; Shigemitsu M; Kodama Y; Itoh S; Konno N; Satoh R; Katagiri T; Kobayashi Y
    J Cardiometab Syndr; 2008; 3(4):200-4. PubMed ID: 19040587
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [PERISCOPE (Pioglitazone Effect on Regression of Intravascular Sonographic Coronary Obstruction Prospective Evaluation) trial].
    Komiyama N
    Nihon Rinsho; 2011 Nov; 69 Suppl 9():331-5. PubMed ID: 22724224
    [No Abstract]   [Full Text] [Related]  

  • 18. Thiazolidinediones: effects on the development and progression of type 2 diabetes and associated vascular complications.
    Krentz A
    Diabetes Metab Res Rev; 2009 Feb; 25(2):112-26. PubMed ID: 19219860
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The BARI 2D study].
    Mafrici A; Briguori C
    G Ital Cardiol (Rome); 2010 Oct; 11(10):711-7. PubMed ID: 21246772
    [No Abstract]   [Full Text] [Related]  

  • 20. Favorable Impact on LDL Particle Size in Response to Treatment With Pioglitazone is Associated With Less Progression of Coronary Atherosclerosis in Patients With Type 2 Diabetes.
    Mani P; Uno K; St John J; Kupfer S; Perez A; Tuzcu EM; Hazen SL; Nissen SE; Nicholls SJ
    J Am Coll Cardiol; 2015 Jul; 66(3):328-329. PubMed ID: 26184626
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.